Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

Blood

Volumn 105, Issue 11, 2005, Pages 4470-4476

  Hamasaki, Makoto ^b   Hideshima, Teru ^b   Tassone, Pierfrancesco ^b   Neri, Paola ^b   Ishitsuka, Kenji ^b   Yasui, Hiroshi ^b   Shiraishi, Norihiko ^b   Raje, Noopur ^b   Kumar, Shaji ^b   Picker, Donald H ^b   Jacob, Gary S ^b   Richardson, Paul G ^b   Munshi, Nikhil C ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; ARSENIC TRIOXIDE; ATIPRIMOD; AZASPIRANE; CASPASE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL KINASE; PROTEIN KINASE B; SOMATOMEDIN C; STAT PROTEIN; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CELL ADHESION; CELL GROWTH; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STROMA CELL; UMBILICAL VEIN;

EID: 21144440687     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3794     Document Type: Article

References (67)

1. Gregory W, Richards M, Malpas J. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10:334-342.
2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16:3832-3842.
3. Fermand J, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment?. Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
4. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95:7-11.
5. Attal M, Harousseau J. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol. 2001;38:226-230.
6. Salmon S, Dalton W, Grogan T, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991;78:44-50.
7. Grogan T, Spier C, Salmon S, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993;81:490-495.
8. Sonneveld P. Drug resistance in multiple myeloma. Pathol Biol (Paris). 1999;47:182-187.
9. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol. 1999;10(suppl 6):53-59.
10. Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol. 2002;19:87-104.
11. Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
12. Damiano J, Dalton W. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38:71-81.
13. Hazlehurst L, Damiano J, Buyuksal I, Pledger W, Dalton W. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;19:4319-4327.
14. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60:6763-6770.
15. Hideshima T, Nakamura N, Chauhan D, Anderson K. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991-6000.
16. Hideshima T, Anderson K. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927-937.
17. Richardson P, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
18. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
19. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004;6:439-444.
20. Albrightson-Winslow C, Brickson B, King A, et al. Beneficial effects of long-term treatment with SKαF 105685 in murine lupus nephritis. J Pharmacol Exp Ther. 1990;255:382-387.
21. Hancock W, Schmidbauer G, Badger A, Kupiec-Wegtinski J. SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. Transplant Proc. 1992;24:231-232.
22. Rabinovitch A, Suarez W, Qin H, Power R, Badger A. Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 106610. J Autoimmun. 1993;6:39-49.
23. Fan P, Albrightson C, Howell D, Best C, Badger A, Coffman T. The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. J Am Soc Nephrol. 1993;3:1680-1685.
24. Badger A, Swift B, Webb E, Clark R, Bugelski P, Griswold D. Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression. Int J Immunopharmacol. 1993;15:343-352.
25. High W, Bugelski P, Nichols M, Swift B, Solleveld H, Badger A. Effects of a novel azaspirane (SK&F 105685) on arthritic lesions in the adjuvant Lewis rat: attenuation of the inflammatory process and preservation of skeletal integrity. J Rheumatol. 1994;21:476-483.
26. Bradbeer J, Kapadia R, Sarkar S, et al. Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. Arthritis Rheum. 1996;39:504-514.
27. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
28. Mitsiades N, Mitsiades C, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374-14379.
29. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
30. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
31. Klein B, Zhang X, Lu Z, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
32. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248-255.
33. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-234.
34. Hideshima T, Chauhan D, Hayashi T, et al. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003;63:8428-8436.
35. Podar K, Tai Y, Davies F, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428-435.
36. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin-and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002;277:7875-7881.
37. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol. 2001;28:560-564.
38. Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102:3340-3348.
39. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1:851-860.
40. Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J. 2001;2:42-53.
41. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
42. + multiple myeloma cells. Blood. 2004;104:3688-3696.
43. Mitsiades N, Mitsiades C, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530.
44. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
45. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159:2212-2221.
46. Georgii-Hemming P, Wiklund H, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250-2258.
47. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol. 1997;97:429-440.
48. Mitsiades C, Mitsiades N, McMullan C, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221-230.
49. Ogata A, Chauhan D, Urashima M, Teoh G, Treon S, Anderson K. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 1997;3:1017-1022.
50. Catlett-Falcone R, Landowski T, Oshiro M, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
51. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29:3945-3950.
52. Epling-Burnette P, Liu J, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351-362.
53. Wei L, Kuo M, Chen C, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a Pl 3-K/Akt pathway. Oncogene. 2001;20:5799-5809.
54. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004;3:1259-1262.
55. Gupta D, Treon S, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.
56. Kumar S, Witzig T, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17:2025-2031.
57. Du W, Hattori Y, Hashiguchi A, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int. 2004;54:285-294.
58. Hideshima T, Richardson P, Anderson K. Novel therapeutic approaches for multiple myeloma. Immunol Rev. 2003;194:164-176.
59. Chauhan D, Pandey P, Ogata A, et al. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chem. 1997;272:29995-29997.
60. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood. 2002;100:194-199.
61. Le Gouill S, Podar K, Amiot M, et al. VEGF induces MCL-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004;104:2886-2892.
62. Mitsiades C, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683.
63. Chauhan D, Hideshima T, Anderson K. Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol. 2003;78:114-120.
64. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87:1104-1112.
65. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
66. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002;62:5019-5026.
67. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003; 101:703-705.